Neural tube defect prevalence 7.0 per 10,000 in HIV-exposed

Neural tube defect prevalence 7.0 per 10,000 in HIV-exposed

January 10, 2020 Neural tube defect prevalence 7.0 per 10,000 in HIV-exposed (HealthDay)—The prevalence of neural tube defects (NTDs) is 7.0 per 10,000 live births in HIV-exposed pregnancies, which is similar to the prevalence in the general population, according to research published in the Jan. 10 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report . Jennita Reefhuis, Ph.D., from the CDC in Atlanta, and colleagues estimated the overall prevalence of NTDs and prevalence of NTDs in HIV-exposed pregnancies during 2013 to 2017 for 15 jurisdictions using linked data from two CDC surveillance programs for HIV/AIDS and birth defects. The researchers found that among women with diagnosed HIV infection, the prevalence of NTDs was 7.0 per 10,000 live births. This prevalence was similar to that in the general population from these 15 jurisdictions (7.0 per 10,000 live births) and the U.S. estimated prevalence based on data from 24 states (approximately 8 per 10,000 live births ). "Continued efforts to collect information on pregnancies affected by maternal HIV infection are needed to understand the association between HIV treatment and birth defects and other pregnancy outcomes," the authors write. Explore further



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More